More Trials For UK PRODIGY GP System

11 August 1996

More in-depth trials have been approved for the PRODIGY (Prescribing Rationally with Decision-support in General Practice Study) computerized decision-support system, which is now being piloted to provide UK general practitioners with clinical advice and prescription options.

Further work on PRODIGY gets underway in January-March 1997, building on the existing R&D program involving 137 English GP practices and five clinical computing firms (VAMP Health, AAH Meditel, EMIS, Genisyst and Medical Care Systems). So far, PRODIGY has been tested in day-to-day patient treatment; immediately the diagnosis is made, it provides the GP with decision support, presenting a choice of three or more drug treatments. It can also present non-drug treatments and patient information leaflets. Phase 2 will involve testing enhanced versions of computer software and therapeutic recommendations.

Health Minister Gerald Malone says he is "encouraged by the early results and the enthusiasm amongst GPs involved in the trial for the next round of studies" found in an interim report on the pilot study. But the Association of the British Pharmaceutical Industry says the report shows "a substantial group of prescribers expressed anxiety over the system....which, clearly, needs considerable revision."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight